Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

And that sounds to me like Novo Nordisk may have just discovered two new revenue streams it can extract from Ozempic. While not super cheap today, at 26 times trailing earnings and with growth ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish kroner ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment. Never before was there a drug that actually worked for weight loss.

So is Ozempic safe? Novo Nordisk, the pharmaceutical company that makes Ozempic and Wegovy, stands behind the safety and efficacy of all its GLP-1 medicines when they’re used as indicated and ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...